References
- Milewicz A, Tworowska U, Demissie M. Menopausal obesity – myth or fact? Climacteric 2001;4:273–83
- Agorastos T, Vaitsi V, Pantazis K, Afstathiadis E, Vavilis D, Bontis JN. Aromatase inhibitor anastrazole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005;118:239–40
- Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 2003;26:27–33
- Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004;64:1213–30
- Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril 2006;86:1447–51
- Shippen ER, West WJ. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;75:305–9
- Hilário SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril 2009;91:240–3
- Clark RV, Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989;10:240–7
- Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002;167:624–9
- Plourde PV, Reiter EO, Jou HC, .Safety and efficacy of anastrazole for the treatment of pubertal gynaecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428–33
- Sit ASY, Modugno F, Hill LM, Marin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiol Biomarkers Prev 2004;13:1459–64